Far‑infrared therapy improves ankle brachial index in hemodialysis patients with peripheral artery disease

October 26, 2019

Abstract

Ankle brachial index (ABI) is a diagnostic tool for peripheral artery disease (PAD), which is an important issue in hemodialysis

(HD) patients. We enrolled 198 maintenance HD patients in this study. PAD is defined as ABI ≤ 0.90. Only PAD

patients received far-infrared (FIR) therapy using the WS TY101 FIR emitter for 40 min during each HD session, three

times weekly for 6 months. The ABI was measured at the bilateral lower extremities for 4 times [pre-dialytic timing (0 min)

and 40 min after the initiation of HD session at both day 0 and 6 months after the FIR therapy]. The primary outcome

is the change in ABI. There were 51 out of 198 patients with PAD. In comparison with the period without FIR therapy

in the 51 PAD patients, 6 months of FIR therapy significantly improved the ABI of the right/left side for 0 min (from

0.77 ± 0.19 to 0.81 ± 0.20, p = 0.027/0.79 ± 0.20 to 0.81 ± 0.17, p = 0.049), 40 min during HD (from 0.73 ± 0.23 to 0.83 ± 0.19,

p < 0.001/from 0.77 ± 0.21 to 0.83 ± 0.18, p < 0.001), and the incremental change between 0 and 40 min (from − 0.04 ± 0.14

to 0.05 ± 0.13, p = 0.007/from − 0.05 ± 0.13 to 0.03 ± 0.11, p = 0.012), respectively. In conclusion, the application of FIR

therapy for 40 min, three times weekly for 6 months, has improved the ABI of both lower extremities, thus providing a new

strategy of PAD treatment in HD patients.

-Heart Vessels (2019) 34: 435-441

Want to know more?



Contact us for more detail


Learn more
Questions to FIRAPY
FIRAPY collaborates with Taipei Veterans General Hospital in research on non-invasive therapies for
July 2, 2025
FIRAPY and Taipei Veterans General Hospital co-published a study in JFMA showing improved cardiovascular and infection outcomes in peritoneal dialysis patients using far-infrared therapy.
June 17, 2025
We are pleased to announce that FIRAPY will be exhibiting at the 70th Annual Meeting of the Japanese Society for Dialysis Therapy (JSDT) , to be held in OSAKA , Japan , from June 27-29, 2025 . 📍 Booth No.: ⑩-96 📅 June 27–29, 2025 📌 Osaka International Convention Center 🔗 Event Website (Japanese) FIRAPY is now adopted by over 200 dialysis facilities across Japan , where it has been used in daily clinical practice to support fistula function maintenance and foot care . With this extensive local experience, FIRAPY has become an important part of non-invasive treatment for Japanese HD patients. We look forward to sharing our latest clinical insights and field experiences at JSDT 2025. If you are attending, we warmly welcome you to stop by Booth ⑩-96 and learn more about how FIRAPY is making a difference in dialysis care. See you in Osaka!
More Posts